Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
30.22
-0.42 (-1.37%)
At close: Mar 10, 2025, 4:00 PM
30.84
+0.62 (2.05%)
Pre-market: Mar 11, 2025, 7:13 AM EST
Janux Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 10.59 | 8.08 | 8.61 | 3.64 | - | |
| Revenue Growth (YoY) | 30.99% | -6.14% | 136.79% | - | - | |
| Cost of Revenue | 68.39 | 54.92 | 53.44 | 26.24 | 3.04 | |
| Gross Profit | -57.8 | -46.84 | -44.83 | -22.6 | -3.04 | |
| Selling, General & Admin | 41.05 | 26.14 | 22.26 | 10.33 | 1.8 | |
| Operating Expenses | 41.05 | 26.14 | 22.26 | 10.33 | 1.8 | |
| Operating Income | -98.85 | -72.98 | -67.09 | -32.93 | -4.84 | |
| Interest Expense | - | - | - | - | -0.21 | |
| Interest & Investment Income | 29.85 | 14.69 | 4.03 | 0.26 | - | |
| EBT Excluding Unusual Items | -68.99 | -58.29 | -63.06 | -32.67 | -5.05 | |
| Other Unusual Items | - | - | - | - | -1.74 | |
| Pretax Income | -68.99 | -58.29 | -63.06 | -32.67 | -6.78 | |
| Net Income | -68.99 | -58.29 | -63.06 | -32.67 | -6.78 | |
| Net Income to Common | -68.99 | -58.29 | -63.06 | -32.67 | -6.78 | |
| Shares Outstanding (Basic) | 54 | 44 | 41 | 24 | 1 | |
| Shares Outstanding (Diluted) | 54 | 44 | 41 | 24 | 1 | |
| Shares Change (YoY) | 22.12% | 6.14% | 76.24% | 2471.20% | 36.71% | |
| EPS (Basic) | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 | |
| EPS (Diluted) | -1.28 | -1.32 | -1.52 | -1.39 | -7.41 | |
| Free Cash Flow | -44.17 | -52.43 | -49.37 | -18.46 | -4.37 | |
| Free Cash Flow Per Share | -0.82 | -1.19 | -1.19 | -0.78 | -4.77 | |
| Operating Margin | -933.58% | -902.87% | -779.04% | -905.39% | - | |
| Profit Margin | -651.62% | -721.18% | -732.22% | -898.32% | - | |
| Free Cash Flow Margin | -417.20% | -648.58% | -573.24% | -507.51% | - | |
| EBITDA | -96.79 | -71.02 | -66.25 | -32.82 | -4.83 | |
| D&A For EBITDA | 2.06 | 1.96 | 0.84 | 0.11 | 0.01 | |
| EBIT | -98.85 | -72.98 | -67.09 | -32.93 | -4.84 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.